Skip to main navigation
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2025
Resources
All Resources
2024 Savings Report
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Search
Close
Breadcrumb
Association for Accessible Medicines
Resources
Press Releases
Press Release
Share
Press Release
Feb 19, 2019
| Rachel Schwartz
Patient Victory: Supreme Court Denies Review of Drug Pricing Law HB 631
Press Release
Feb 13, 2019
| Rachel Schwartz
AAM Welcomes Re-Introduction of the PACED Act
Press Release
Feb 8, 2019
| Rachel Schwartz
Statement from the Association for Accessible Medicines on the Introduction of the CREATES Act
Press Release
Feb 7, 2019
| Rachel Schwartz
AAM: Congress Should Reject Hatch-Waxman Integrity Act of 2019
Press Release
Feb 4, 2019
| Jewel Smith
AAM Announces 2019 Board of Directors
Press Release
Feb 1, 2019
| Rachel Schwartz
AAM Statement on Trump Administration’s Proposal to Lower Drug Costs by Targeting Backdoor Rebates
Press Release
Dec 13, 2018
| Rachel Schwartz
AAM Statement on FDA Withdrawal of Generic Drug Labeling Rule
Press Release
Dec 10, 2018
| Rachel Schwartz
Andrew O’Connor Joins AAM as Manager, State Government Affairs
Press Release
Nov 30, 2018
| Rachel Schwartz
AAM Statement on Signing of USMCA by President
Press Release
Nov 14, 2018
| Rachel Schwartz
Poll Results: Americans’ Attitudes on U.S. Trade Policy and Drug Pricing
Press Release
Nov 5, 2018
| Rachel Schwartz
Patient Groups, Retirees, American Workers, Doctors, Manufacturers, Join to Voice Concern Over Proposed Trade Deal
Press Release
Oct 17, 2018
| Rachel Schwartz
AAM Files Amicus Brief in Helsinn v Teva
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2025
Resources
All Resources
2024 Savings Report
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action